纽约/伦敦 - 生物技术公司 Compass Pathways plc (NASDAQ:CMPS) 周二宣布与全国性介入精神病学实践网络Radial Health, Inc.建立战略合作关系,这标志着其第七个此类合作伙伴关系。据 InvestingPro 数据显示,这家市值约6.3亿美元的生物技术公司在过去六个月内股价飙升超过101%。
Investing.com -- 周三盘前交易中, Compass Pathways Plc (NASDAQ:CMPS) 股价上涨3%,此前该公司宣布美国食品药品监督管理局已接受其COMP360的研究性新药申请,使其能够开始对创伤后应激障碍患者进行后期临床试验。
The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...
LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...
COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...
Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...
All right. Good morning, everyone. Welcome to the session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. I'm just going to start off with ...
COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-0.38 EPS, expectations were $-0.37. Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings ...